GCG and type 2 diabetes mellitus: Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review